HC Wainwright & Co. Reiterates Buy on Aclaris Therapeutics, Maintains $16 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 90.3%

Neg 0% Neu 90.3% Pos 0%

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and maintains $16 price target.